Isofol Medical Initiates Clinical Study for Arfolitixorin in Colorectal Cancer

The latest update is out from Isofol Medical AB ( (SE:ISOFOL) ).

Isofol Medical AB has commenced a clinical phase Ib/II study for its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the efficacy of arfolitixorin as part of the standard 5-FU-based first-line therapy. The trial will proceed in two stages, with the initial phase assessing the benefit/risk profile of escalating doses, followed by a comparison of the highest dose with a lower dose. This milestone marks a significant step towards bringing arfolitixorin closer to market, with the potential to significantly impact treatment outcomes for patients with advanced cancers.

More about Isofol Medical AB

Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company is developing a drug candidate, arfolitixorin, which aims to enhance the efficacy of first-line standard treatments for various solid tumors, particularly in colorectal cancer, where there is a significant need for improved therapies. Isofol Medical AB is publicly traded on Nasdaq Stockholm.

YTD Price Performance: -15.76%

Technical Sentiment Signal: Buy

Current Market Cap: €27.86M

Find detailed analytics on ISOFOL stock on TipRanks’ Stock Analysis page.